Block, Matthew S.

Bowtell, David D.

Brown, B.

Brown, S.

Brucker, Sara Y.

Cazorla, Alicia

Chenevix-Trench, Georgia

Chudecka-Glaz, Anita

de Andrade, Jurandyr M.

de Sousa, Christiani B.

Edwards, Robert P.

Eilber, Ursula

Fereday, Sian

Gao, Bo

García-Bueno, José M.

Ghatage, Prafull

Harnett, Paul R.

Hartkopf, Andreas D.

Hernandez, Brenda Y.

Herpel, Esther

Hill, J.

Hung, Jillian

Intermaggio, Maria P.

Jensen, Allan

Jimenez-Linan, Mercedes

Johnatty, Sharon E.

Jung, Audrey Y.

Kalli, Kimberly R.

Kennedy, Catherine J.

Lester, Jenny

Li, Zheng

Links, M.

Longacre, Teri A.

Lubinski, Jan

Mack, Marie

McCauley, Bryan M.

McGuire, Valerie

Menkiszak, Janusz

Modugno, Francesmary

Nelson, Gregg

Ness, Roberta B.

Orsulic, Sandra

Oszurek, Oleg

Paz-Ares, Luis

Rambau, Peter F.

Ramón y Cajal, Teresa

Rothstein, Joseph H.

Sharma, Raghwa

Sieh, Weiva

Sinn, Peter

Taran, Florin Andrei

Tiezzi, Daniel G.

Toloczko, Aleksandra

Traficante, Nadia

Vierkant, Robert A.

Wagner, Philipp

Winham, Stacey J.

English

Objective: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. Patients and Methods: We conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong). Results: Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P&lt;.001 for both). In HGSOC, strong MyD88 expression was modestly associated with shortened overall survival (hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P=.04) but was also associated with advanced stage (P&lt;.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable survival (HR [95% CI], 0.49 [0.29-0.84] and 0.44 [0.21-0.89], respectively; P=.009 and P=.02, respectively). Conclusion: Results are consistent with an association between strong MyD88 staining and advanced stage and poorer survival in HGSOC and demonstrate correlation between strong MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological differences between the 2 serous histotypes.</p

Bond University Research Portal

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

https://pure.bond.edu.au/ws/files/216425480/MyD88_and_TLR4_Expression_in_Epithelial_Ovarian_Cancer.pdf

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

Abstract

Similar works

Full text

Available Versions

Bond University Research Portal